Skip to main content

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis

The acquisition of Nucleis will:Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and Germany Expand CDMO capabilities to support the development of innovative PET tracers in oncology, neurology, and cardiologyPARIS, April 10, 2025 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs. Founded in 2017 as a spin-off from the University of Liège (Cyclotron Research Center, Belgium), Nucleis has established itself as a key player in PET imaging radiopharmaceuticals. Nucleis manufactures and distributes FDG in...

Continue reading

MergeCo to be named Elevra Lithium and Board Nominees Announced

BRISBANE, Australia, April 10, 2025 (GLOBE NEWSWIRE) — Sayona Mining Limited (“Sayona” or “Company”) (ASX:SYA; OTCQB:SYAXF) provides an update on the proposed transaction with Piedmont Lithium Inc. (“Piedmont Lithium”) (NASDAQ:PLL, ASX:PLL) (see announcement on 19 November 2024) (the “Transaction”) that will combine the two companies to create a leading lithium business. Subject to Sayona shareholder approval, the name of the Company will be changed to Elevra Lithium Limited (“Elevra Lithium”) upon completion of the Transaction. Further details on the name, brand and logo will be provided closer to the Transaction completion. Additionally, the nominees to the Board of Elevra Lithium have now been agreed. As previously announced, subject to and with effect from completion of Transaction, the Elevra Lithium Board will initially consist...

Continue reading

Glacier Bancorp Receives Final Regulatory Approvals for Its Acquisition of Bank of Idaho Holding Co.

KALISPELL, Mont., April 09, 2025 (GLOBE NEWSWIRE) — Glacier Bancorp, Inc. (NYSE: GBCI) today announced that all regulatory approvals required in connection with its previously announced acquisition of Bank of Idaho Holding Co. (“BOID”) (OTCQX: BOID), and its bank subsidiary, Bank of Idaho, have been received. The transaction is scheduled to be completed April 30, 2025, subject to the satisfaction of remaining conditions to closing set forth in the merger agreement, including approval by BOID shareholders at a special meeting of shareholders now scheduled for April 21, 2025. About Glacier Bancorp, Inc.Glacier Bancorp, Inc. is the parent company for Glacier Bank and its bank divisions: Altabank (American Fork, UT), Bank of the San Juans (Durango, CO), Citizens Community Bank (Pocatello, ID), Collegiate Peaks Bank (Buena Vista, CO),...

Continue reading

Almadex Acquires Three New Gold Exploration Projects by Staking in the Western USA, Surface Sampling returns 3.5 g/t Gold

VANCOUVER, British Columbia, April 09, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce that it has acquired three new gold-silver early-stage exploration projects by staking. The projects are located in Nevada and New Mexico. Summaries of the work and results returned to date are as follows. Big Sky Project, New MexicoThe Big Sky high sulphidation epithermal gold-silver project is located in western New Mexico and covers a large area of advanced argillic alteration and silicification hosted in rhyolite volcanics. Zones of hydrothermal brecciation occur along with quartz-alunite and dickite alteration. To date 57 grab rock samples have been taken from outcrop and subcrop (grab samples are selected samples and may not represent true underlying...

Continue reading

Regulatory Approval Achieved For Snai Acquisition

Regulatory approval achieved for Snai acquisition, enhancing Flutter’s position in Italy, Europe’s largest regulated market NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces that it has received all necessary antitrust, gaming and regulatory confirmations to acquire Snaitech S.p.A. (“Snai”), one of Italy’s leading omni-channel operators. The acquisition of Snai fully aligns with Flutter’s strategy to invest in leadership positions in attractive international markets, creating value through providing access to Flutter’s market leading products and capabilities. Adding Snai to the Flutter portfolio will consolidate Flutter’s leadership...

Continue reading

ProVen VCT plc: Allotment update

ProVen VCT plc (the “Company”) Allotment Update 09 April 2025 On 6 November 2024, the Company and ProVen Growth and Income VCT plc published a prospectus (comprising a securities note, registration document and summary (the “Prospectus”)) in relation to a joint offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies, with an over-allotment facility of up to a further £10,000,000 in aggregate (the “Offer”). The Prospectus noted that the first allotment for the 2025/2026 Offer was expected to occur on or around 11 April 2025. Given current volatility in public stock markets, the Company intends to delay the allotment date to on or around 30 April 2025. Beringea LLPCompany SecretaryTelephone 020 7845 7820 -End-

Continue reading

ProVen Growth and Income VCT plc: Allotment Update

ProVen Growth and Income VCT plc (the “Company”) Allotment Update 09 April 2025 On 6 November 2024, the Company and ProVen VCT plc published a prospectus (comprising a securities note, registration document and summary (the “Prospectus”)) in relation to a joint offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies, with an over-allotment facility of up to a further £10,000,000 in aggregate (the “Offer”). The Prospectus noted that the first allotment for the 2025/2026 Offer was expected to occur on or around 11 April 2025. Given current volatility in public stock markets, the Company intends to delay the allotment date to on or around 30 April 2025.  Beringea LLPCompany SecretaryTelephone 020 7845 7820 -End-

Continue reading

CareSource completes acquisition of Commonwealth Care Alliance to strengthen care for Massachusetts residents with significant needs

Members and patients will continue to receive coordinated services from their same care teams and providers, supported by capabilities of a leading nonprofit managed care organizationErhardt PreitauerErhardt Preitauer is the president and CEO of CareSource.DAYTON, Ohio and BOSTON, April 09, 2025 (GLOBE NEWSWIRE) — CareSource, a nationally recognized, nonprofit managed care organization, today completed the acquisition* of Commonwealth Care Alliance (CCA), a nonprofit, mission-driven health care services organization that offers innovative health plans and care delivery programs designed for individuals with the most significant needs.   CCA will continue to operate its Senior Care Options (SCO) and One Care plans along with its clinical delivery programs under the CareSource Family of Brands. CCA’s members and patients...

Continue reading

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) — Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro’s merger with BioSymetrics is designed to enhance Renovaro’s data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro’s AI powered biomarker and diagnostic platform. At the core of this potential synergy is BioSymetrics’ proprietary...

Continue reading

DemandScience Invests in the Future of AI for B2B Revenue Marketing with Acquisitions of Bound and DemandJump

Company Accelerates AI Vision and Leadership with Strategic Acquisitions and names Greg Jordan Chief Product OfficerSmarter Together: A Bold Step Into AI-Powered GrowthDemandScience Acquires Bound and DemandJumpBOSTON, MA, April 09, 2025 (GLOBE NEWSWIRE) — DemandScience, a global revenue marketing company, today announced the acquisition of Bound, a leader in AI-driven website personalization, and DemandJump, a marketing strategy platform specializing in search behavior insights. These investments further DemandScience’s AI-driven vision, enabling marketers with intelligent predictive analytics, and data-powered strategies. Alongside these acquisitions, Greg Jordan has been promoted to Chief Product Officer, reinforcing the company’s long-term commitment to AI-driven solutions. This news means DemandScience is on track...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.